Skip to main content

Yesterday, April 13, 2016, 43 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $4.16 to $2,804,186.25.

Highlighted Stocks Traded by Insiders:

Wayfair (W) - FREE Research Report

Savarese James, who is Chief Operating Officer at Wayfair, sold 500 shares at $41.07 on April 13, 2016. Following this transaction, the Chief Operating Officer owned 602,397 shares meaning that the stake was reduced by 0.08% with the 500-share transaction.

Macri Edmond, who is Chief Product at Wayfair, sold 500 shares at $39.81 on April 13, 2016. Following this transaction, the Chief Product owned 237,856 shares meaning that the stake was reduced by 0.21% with the 500-share transaction.

The shares most recently traded at $42.19, up $2.38, or 5.64% since the insider transaction. Historical insider transactions for Wayfair go as follows:

  • 4-Week # shares bought: 7,000
  • 4-Week # shares sold: 10,937
  • 12-Week # shares bought: 7,000
  • 12-Week # shares sold: 461,224
  • 24-Week # shares bought: 7,000
  • 24-Week # shares sold: 769,206

The average volume for Wayfair has been 1.3 million shares per day over the past 30 days. Wayfair has a market cap of $3.5 billion and is part of the services sector and retail industry. Shares are down 11.44% year-to-date as of the close of trading on Wednesday.

Wayfair Inc. engages in the e-commerce business in the United States. It offers approximately seven million products for the home under various brands. Currently, there are 6 analysts who rate Wayfair a buy, no analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on W - FREE

TheStreet Quant Ratings

TheStreet Recommends

rates Wayfair as a

sell

. Among the areas we feel are negative, one of the most important has been poor profit margins. Get the full

Wayfair Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Gevo (GEVO) - FREE Research Report

Gruber Patrick R., who is Chief Executive Officer at Gevo, sold 108 shares at $0.26 on April 13, 2016. Following this transaction, the Chief Executive Officer owned 37,894 shares meaning that the stake was reduced by 0.28% with the 108-share transaction.

Ryan Christopher Michael, who is President and COO at Gevo, sold 121 shares at $0.26 on April 13, 2016. Following this transaction, the President and COO owned 35,061 shares meaning that the stake was reduced by 0.34% with the 121-share transaction.

Roda Gregory, who is Chief Commercial Officer at Gevo, sold 16 shares at $0.26 on April 13, 2016. Following this transaction, the Chief Commercial Officer owned 7,936 shares meaning that the stake was reduced by 0.2% with the 16-share transaction.

Willis Mike, who is Cfo at Gevo, sold 21 shares at $0.26 on April 13, 2016. Following this transaction, the Cfo owned 25,714 shares meaning that the stake was reduced by 0.08% with the 21-share transaction.

The shares most recently traded at $0.24, down $0.02, or 8.33% since the insider transaction. Historical insider transactions for Gevo go as follows:

  • 4-Week # shares bought: 181,484
  • 4-Week # shares sold: 118
  • 12-Week # shares bought: 181,484
  • 12-Week # shares sold: 4,775
  • 24-Week # shares bought: 181,484
  • 24-Week # shares sold: 6,547

The average volume for Gevo has been 633,200 shares per day over the past 30 days. Gevo has a market cap of $5.2 million and is part of the basic materials sector and chemicals industry. Shares are down 61.11% year-to-date as of the close of trading on Wednesday.

Gevo, Inc., a renewable chemicals and biofuels company, focuses on the development and commercialization of alternatives to petroleum-based products based on isobutanol produced from renewable feedstocks. It operates in two segments, Gevo, Inc. and Gevo Development/Agri-Energy. Currently, there is 1 analyst who rates Gevo a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on GEVO - FREE

TheStreet Quant Ratings

rates Gevo as a

sell

. The company's weaknesses can be seen in multiple areas, such as its generally disappointing historical performance in the stock itself and weak operating cash flow. Get the full

Gevo Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

LDR (LDRH) - FREE Research Report

Richard Patrick, who is EVP, European Sales, Medical at LDR, sold 25,000 shares at $26.50 on April 13, 2016. Following this transaction, the EVP, European Sales, Medical owned 553,463 shares meaning that the stake was reduced by 4.32% with the 25,000-share transaction.

The shares most recently traded at $26.50, up $0.00, or 0% since the insider transaction. Historical insider transactions for LDR go as follows:

  • 4-Week # shares bought: 110,000
  • 4-Week # shares sold: 5,232
  • 12-Week # shares bought: 110,000
  • 12-Week # shares sold: 5,232
  • 24-Week # shares bought: 110,000
  • 24-Week # shares sold: 5,626

The average volume for LDR has been 496,300 shares per day over the past 30 days. LDR has a market cap of $784.0 million and is part of the health care sector and health services industry. Shares are up 6.89% year-to-date as of the close of trading on Wednesday.

LDR Holding Corporation, a medical device company, focuses on designing and commercializing various surgical technologies for the treatment of patients suffering from spine disorders in the United States and internationally. Currently, there are 6 analysts who rate LDR a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on LDRH - FREE

TheStreet Quant Ratings

rates LDR as a

sell

. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, weak operating cash flow and generally disappointing historical performance in the stock itself. Get the full

LDR Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.